Comparison · NCT00618436-7d4133c1
Levetiracetam vs Phenytoin: Seizure Incidence
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Levetiracetam vs Phenytoin: Seizure Incidence. Trial comparisons, record NCT00618436-7d4133c1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00618436-7d4133c1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.147 | 0.0645 | 0.301 | wilson | |
| Risk in group 2 | 0.167 | 0.0584 | 0.392 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0196 | -0.26 | 0.169 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.882 | 0.238 | 3.28 | log | |
| Odds ratio, group 1 over group 2 | 0.862 | 0.181 | 4.11 | log | |
| Number needed to treat, for one fewer participant with the outcome on Levetiracetam than on Phenytoin | 51 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Levetiracetam | This group will receive treatment with Levetiracetam. | 5 | 34 | OG000 |
| Group 2 | Phenytoin | This group will receive treatment with Phenytoin. | 3 | 18 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Seizure Incidence
- Description
- This was the number of patients in each group who demonstrated seizure activity during the course of the study
- Time frame
- Duration of study, up to 6 months after the injury
- Population
Source ClinicalTrials.gov
Trial
- Title
- Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention
- NCT number
- NCT00618436
- Phases
- PHASE4
- Conditions
- Traumatic Brain Injury, Subarachnoid Hemorrhage
- Interventions
- Levetiracetam, Phenytoin
- Lead sponsor
- University of Cincinnati
- Results first posted
- 2014-04-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00618436?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00618436-7d4133c1